212 related articles for article (PubMed ID: 28486366)
1. Changes in Myomectomy Practice After the U.S. Food and Drug Administration Safety Communication on Power Morcellation.
Stentz NC; Cooney LG; Sammel M; Shah DK
Obstet Gynecol; 2017 Jun; 129(6):1007-1013. PubMed ID: 28486366
[TBL] [Abstract][Full Text] [Related]
2. Racial Disparities in Response to a US Food and Drug Administration Safety Communication Regarding the Use of Power Morcellation for the Treatment of Uterine Leiomyoma.
Matsushita T; Sekizawa A; Jacobs LK
J Minim Invasive Gynecol; 2020 Jan; 27(1):178-185.e1. PubMed ID: 30936031
[TBL] [Abstract][Full Text] [Related]
3. Association of the U.S. Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and Myomectomy.
Barron KI; Richard T; Robinson PS; Lamvu G
Obstet Gynecol; 2015 Dec; 126(6):1174-1180. PubMed ID: 26595561
[TBL] [Abstract][Full Text] [Related]
4. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation.
Harris JA; Swenson CW; Uppal S; Kamdar N; Mahnert N; As-Sanie S; Morgan DM
Am J Obstet Gynecol; 2016 Jan; 214(1):98.e1-98.e13. PubMed ID: 26314519
[TBL] [Abstract][Full Text] [Related]
5. Minilaparotomy Versus Laparoscopic Myomectomy After Cessation of Power Morcellation: Rate of Wound Complications.
Dubin AK; Wei J; Sullivan S; Udaltsova N; Zaritsky E; Yamamoto MP
J Minim Invasive Gynecol; 2017; 24(6):946-953. PubMed ID: 28552622
[TBL] [Abstract][Full Text] [Related]
6. Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.
Multinu F; Casarin J; Hanson KT; Angioni S; Mariani A; Habermann EB; Laughlin-Tommaso SK
JAMA Surg; 2018 Jun; 153(6):e180141. PubMed ID: 29641835
[TBL] [Abstract][Full Text] [Related]
7. Association of Patient Race With Surgical Practice and Perioperative Morbidity After Myomectomy.
Stentz NC; Cooney LG; Sammel MD; Shah DK
Obstet Gynecol; 2018 Aug; 132(2):291-297. PubMed ID: 29995738
[TBL] [Abstract][Full Text] [Related]
8. Trends in Mode of Hysterectomy After the U.S. Food and Drug Administration Power Morcellation Advisory.
Ottarsdottir H; Cohen SL; Cox M; Vitonis A; Einarsson JI
Obstet Gynecol; 2017 Jun; 129(6):1014-1021. PubMed ID: 28486371
[TBL] [Abstract][Full Text] [Related]
9. Change in Surgical Practice for Women With Leiomyomas After the U.S. Food and Drug Administration Morcellator Safety Communication.
Clark NM; Schembri M; Jacoby VL
Obstet Gynecol; 2017 Nov; 130(5):1057-1063. PubMed ID: 29016511
[TBL] [Abstract][Full Text] [Related]
10. Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation.
Lum DA; Sokol ER; Berek JS; Schulkin J; Chen L; McElwain CA; Wright JD
J Minim Invasive Gynecol; 2016; 23(4):548-56. PubMed ID: 26827905
[TBL] [Abstract][Full Text] [Related]
11. Laparoscopic versus abdominal myomectomy: practice patterns and health care use in British Columbia.
Chen I; Lisonkova S; Joseph KS; Williams C; Yong P; Allaire C
J Obstet Gynaecol Can; 2014 Sep; 36(9):817-821. PubMed ID: 25222361
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Morcellation Techniques at the Time of Laparoscopic Hysterectomy and Myomectomy.
Meurs EAIM; Brito LG; Ajao MO; Goggins ER; Vitonis AF; Einarsson JI; Cohen SL
J Minim Invasive Gynecol; 2017; 24(5):843-849. PubMed ID: 28483536
[TBL] [Abstract][Full Text] [Related]
13. Laparoscopic myomectomy and morcellation: A review of techniques, outcomes, and practice guidelines.
Glaser LM; Friedman J; Tsai S; Chaudhari A; Milad M
Best Pract Res Clin Obstet Gynaecol; 2018 Jan; 46():99-112. PubMed ID: 29078975
[TBL] [Abstract][Full Text] [Related]
14. Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy.
Wright JD; Tergas AI; Cui R; Burke WM; Hou JY; Ananth CV; Chen L; Richards C; Neugut AI; Hershman DL
JAMA Oncol; 2015 Apr; 1(1):69-77. PubMed ID: 26182307
[TBL] [Abstract][Full Text] [Related]
15. Temporal trends in minimally invasive myomectomy before and after the US Food and Drug Administration recommendation against electric morcellation.
Pereira N; Frankel WC; Hutchinson AP; Patel HH; Mostisser C; Elias RT
Int J Gynaecol Obstet; 2017 Jun; 137(3):295-300. PubMed ID: 28218964
[TBL] [Abstract][Full Text] [Related]
16. Laparoscopic Hysterectomy Route, Resource Use, and Outcomes: Change After Power Morcellation Warning.
Desai VB; Wright JD; Lin H; Gross CP; Sallah YH; Schwartz PE; Xu X
Obstet Gynecol; 2019 Aug; 134(2):227-238. PubMed ID: 31348209
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 30-day Complication Rates between Laparoscopic Myomectomy and Total Laparoscopic Hysterectomy for the Treatment of Uterine Leiomyoma in Women Older Than Age 40.
Sheyn D; Bretschnieder CE; Mahajan ST; El-Nashar S; Billow M; Ninivaggio CS
J Minim Invasive Gynecol; 2019; 26(6):1076-1082. PubMed ID: 30385429
[TBL] [Abstract][Full Text] [Related]
18. Myomectomy associated blood transfusion risk and morbidity after surgery.
Kim T; Purdy MP; Kendall-Rauchfuss L; Habermann EB; Bews KA; Glasgow AE; Khan Z
Fertil Steril; 2020 Jul; 114(1):175-184. PubMed ID: 32532486
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal Washings After Power Morcellation in Laparoscopic Myomectomy: A Pilot Study.
Toubia T; Moulder JK; Schiff LD; Clarke-Pearson D; O'Connor SM; Siedhoff MT
J Minim Invasive Gynecol; 2016; 23(4):578-81. PubMed ID: 26867701
[TBL] [Abstract][Full Text] [Related]
20. Sydney contained in bag morcellation for laparoscopic myomectomy.
Kanade TT; McKenna JB; Choi S; Tsai BP; Rosen DM; Cario GM; Chou D
J Minim Invasive Gynecol; 2014; 21(6):981. PubMed ID: 25048568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
